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Abstract Noroviruses (NoVs) are one of the leading
causes of acute gastroenteritis worldwide. NoV GII-4 VP1
protein was expressed in a recombinant baculovirus system
using Sf9 insect cells. Several methods for purification and
concentration of virus-like particles (VLPs) were evalu-
ated. Electron microscopy (EM) and histo-blood group
antigen (HBGA) binding assays showed that repeated
sucrose gradient purification followed by ultrafiltration
resulted in intact VLPs with excellent binding to H type 3
antigens. VLPs were stable for at least 12 months at 4C,
and up to 7 days at ambient temperature. These findings
indicate that this method yielded stable and high-quality
VLPs.
Noroviruses (NoVs) cause sporadic acute nonbacterial
gastroenteritis in all age groups [12, 13]. NoVs are divided
into five genogroups, GI to GV, of which GI and GII strains
mostly affect humans [21]. Recently, NoV genotype GII-4
has been responsible for the majority of sporadic gastro-
enteritis cases and outbreaks [13]. The NoV genome con-
sists of a single-stranded RNA of about 7.6 kb, organized
into open reading frames (ORF 1–3). ORF-1 codes for the
RNA-dependent RNA polymerase, and ORF-2 and -3
encode the two structural proteins VP1 and VP2 [10].
Expression of the capsid VP1 gene by recombinant
baculoviruses leads to self-assembly into empty virus-like
particles (VLPs) that are morphologically and antigenically
similar to native NoV [9]. NoV VLPs are widely used as
antigens in diagnostic serological assays and as candidate
vaccines against NoVs [2, 7]. NoV VLPs are highly stable
and resistant to variable conditions, particularly to low pH
[1, 9].
There are limitations in NoV VLP production in terms
of inadequate yield and quality of the VLPs [1, 3, 9, 20].
Both sucrose and CsCl gradients ultracentrifugation have
been used for purification of NoV VLPs [1, 7, 9, 17], even
though studies on rotavirus-like particles demonstrated a
low yield and impurities resulting from CsCl gradient
purification [16].
In the present study, we compared commonly used
methods for NoV GII-4 VLP purification [1, 14, 17] and
concentration [6, 19], considering the purity, yield, mor-
phological integrity, antigenicity and functionality of the
purified VLPs.
The steps for cloning the NoV GII-4 (GenBank sequence
database accession number AF080551) full-length capsid
gene are described elsewhere [11].
VLPs were produced in Sf9 insect cells infected with the
recombinant baculovirus according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Baculovirus titers
expressed as the multiplicity of infection (MOI) of the P2
stocks were determined using a BacPak Rapid Titer Kit
(Clontech Laboratories, Mountain View, CA).
At day 6, infected cell culture (200 ml) was clarified
by centrifugation at 30009g for 30 min at 4C. VLPs in
the supernatant were concentrated by ultracentrifugation
(L8-60M ultracentrifuge, Beckman SW-32.1 Ti rotor) at
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100,0009g for 2 h at 4C, and pellets were resuspended in
0.2 M Tris–HCl, pH 7.3. VLPs were loaded onto a 10–60%
discontinuous sucrose gradient and ultracentrifugated at
100,0009g for 1 h at 4C as described before [17]. Frac-
tions were collected by bottom puncture. The fractions
containing VLPs were pooled. An additional discontinuous
sucrose gradient (35–60%) ultracentrifugation was per-
formed. Sucrose was removed by overnight dialysis against
1 liter of PBS. VLPs were concentrated by dialysis against
polyethylene glycol (PEG; 50%) [6] or by ultrafiltration
[19]. VLPs were concentrated using an Amicon Ultra
30 kDa centrifuge filter device (Millipore Corporation,
Billerica, Germany). VLPs were stored at 4C in PBS.
Alternatively, a less time-consuming sucrose density
gradient purification method was employed [14]. Clarified
supernatants were pelleted twice by ultracentrifugation.
Pellets were resuspended in 0.2 M Tris–HCl, pH 7.3, and
placed on a discontinuous sucrose density gradient
(10–60%) for ultracentrifugation at 100,0009g for 16 h at
4C. The VLP band, which was visible at the 35% sucrose
layer, was collected. Sucrose was removed by dialysis
against 1 liter of PBS, and VLPs were concentrated by
ultracentrifugation at 100,0009g for 2 h at 4C.
In addition, clarified supernatants were concentrated, and
the pellets were resuspended in sterile water. VLPs were
sedimented by ultracentrifugation through cesium chloride
(CsCl) (0.4 g/ml) at 116,0009g for 18 h at 4C as described
earlier by others [1]. CsCl was removed by dialysis against
PBS, and VLPs were concentrated using an Amicon
Ultrafilter.
The total protein content of the purified VLP preparation
was determined using the Pierce BCA Protein Assay
(Thermo Science, Rockford, USA). Endotoxin levels in the
VLP preparations were quantified using the Limulus ame-
bocyte lysate (LAL) assay (Lonza, Walkersville, MD, USA).
The level of endotoxin was\0.1 EU/10 lg of protein, which
is below the international standard of B30 EU/20 lg of
protein [15]. All samples were analyzed for protein expres-
sion by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and western blot. The presence of
NoV VLPs was verified by electron microscopy (EM). VLP
preparations were negatively stained with 3% uranyl acetate
(UA), pH 4.6. The VLPs were examined using an FEI Tecnai
F12 electron microscope operating at 120 kV.
Binding of GII-4 VLPs to carbohydrate receptors was
examined by the histo-blood group antigen (HBGA) binding
assay as described by others [18], with slight modifications.
Briefly, VLPs were coated at 50 ng/well, and synthetic
biotinylated H type 3 and Lewisb histo-blood group carbo-
hydrates (Lectinity Holdings Inc. Moscow, Russia) were
used in serial threefold dilutions, starting from 6 lg/ml.
Wells lacking the synthetic carbohydrates were used as a
negative control.
The conditions for Sf9 cell infections were optimized in
order to obtain a high yield of the VLPs. For recombinant
baculovirus P2 stock, an MOI of 1 was found to be optimal,
and VLPs were harvested from the supernatant after 6 days
of infection. VLPs were further purified by several differ-
ent procedures, as described in Fig. 1a.
The best yield (2–3 mg/200 ml) was obtained after the
purification procedure described in Fig. 1a, panel B. In
comparison, the method described in Fig. 1a, panel C, yiel-
ded a ten times lower amount of NoV capsid VLPs. The
purity of the VLPs obtained by each method was determined
by 12% SDS-PAGE and staining of the proteins with Page-
Blue (Fig. 1b). 1 lg of the total protein was loaded into each
lane. Each method resulted in equally pure protein bands
corresponding to the size of the NoV capsid. Residual PEG
present in the VLPs, concentrated by PEG dialysis, may have
interfered with the protein concentration determination, and
Fig. 1 Purification, concentration and characterization of NoV VLPs.
a Several purification procedures (A–D) were used, and the purity,
morphology, antigenicity and yield of the VLPs were compared.
b NoV capsid protein analysis by 12% SDS-PAGE. c Western blot
analysis using a human convalescent serum against norovirus GII-4.
d EM of purified NoV VLPs observed at a magnification of 930,000.
Bar 100 nm. Samples from purification procedures A, B, C, and
D correspond to lanes and panels A, B, C, and D, respectively.
M protein weight marker
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this could explain the lower capsid protein concentration
observed (Fig. 1b, lane A). NoV capsid identity and anti-
genicity of the VLPs were assayed by western blot using
human NoV-specific convalescent sera (Fig. 1c). The results
show pure NoV capsid proteins without degradation and with
similar antigenicity for each of the purification methods.
Next, we determined the morphological integrity and
homogeneity of the VLPs by EM (Fig. 1d). The VLPs
obtained by purification with sucrose density gradients fol-
lowed by dialysis and either ultrafiltration (Fig. 1d, panel B)
or ultracentrifugation (Fig. 1d, panel C) were approximately
38 nm in size, with the classical appearance of NoV capsid
VLPs. By contrast, CsCl purification (Fig. 1d, panel D) and
concentration of the VLPs by dialysis against PEG (Fig. 1d,
panel A) resulted in VLPs of heterogeneous size, which
appeared broken and aggregated. The VLPs purified and
concentrated by the method schematically presented in
Fig. 1a, panel B, were of the best quality and were subjected
to further analysis.
To determine the optimal storage conditions and stability
of the NoV capsid VLPs, VLPs were treated under different
conditions, and the samples were analyzed by SDS-PAGE to
test their protein integrity (Fig. 2a) and by EM to examine
their morphology (Fig. 2b). VLPs were stable for at least 12
months at 4C in PBS, pH 7.4 (Fig. 2a and b, panel 1), and
at room temperature (23C) up to 7 days (Fig. 2a and b,
panel 3). The VLPs withstood the sterile filtration conditions
when 0.22-lm filters (Durapore, Millipore, Ireland) were
used. Next, we intentionally disrupted the VLP morphology
by heat treatment at 60C for 1 h (Fig. 2b, panel 4) [1]
without degrading the capsid protein (Fig. 2a, lane 4).
An HBGA binding assay [8, 18] was used to test the
functionality of the purified VLPs as well as to determine
the significance of the conformational binding sites on the
VLP, which would presumable require intact VLPs. A
comparison of the binding of VLPs purified by sucrose
gradient centrifugation and by CsCl sedimentation, as well as
heat-treated VLPs (60C, 1 h), to synthetic biotinylated H
type 3 carbohydrate is shown in Fig. 3. The binding was
clearly dependent on the morphology and preserved struc-
ture of the VLPs, with the lowest level of binding observed
with the heat-treated VLPs with disrupted conformational
binding sites. Lewisb antigen was used as a control in the
assay, and this did not bind to any of the VLPs (Fig. 3).
NoV VLPs have been used extensively to study protein
interactions [8], and virus assembly [17], and have been
used as a tool in diagnostic serological assays [7]. Clinical
trials have been performed with the NoV VLPs used as a
vaccine [2]. For all these applications, high-quality VLPs
would be preferable. In this study, different methods of
VLP purification and concentration were used, and the
purity, integrity, morphology, antigenicity and functional-
ity of the GII-4 NoV VLP preparations were examined.
VLPs purified by each method (Fig. 1a, methods A–D)
had a similar appearance and migration pattern on the SDS-
PAGE gel. A western blot with a human convalescent
serum from an individual infected with GII-4 confirmed the
identity of the capsids and the lack of degradation products.
The reason for the lower protein yield after purification
procedure C might have been that a narrow visible band of
VLPs was collected from 35% sucrose, causing some of the
protein to be omitted, thus affecting the yield. However, a
yield of up to 2–3 mg of VLPs, which was obtained by the
best purification method described in the present study, is
remarkably high when compared to other reports [3, 4].
EM analysis of the morphological integrity and homo-
geneity of the VLPs showed that VLPs obtained by puri-
fication with sucrose density gradients followed by
ultrafiltration or ultracentrifugation (procedures B and C,
Fig. 2 Stability of NoV VLPs. The stability was analyzed by SDS-
PAGE (a) and EM (b) at a magnification of 930,000. Bar 100 nm.
NoV capsid VLPs after 8 months at 4C (lane 1 and panel 1), sterile
filtration (lane 2 and panel 2), 7 days at room temperature (lane 3 and
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Fig. 3 Binding of NoV VLPs to synthetic ABH histo-blood group
antigens. Sucrose-purified VLPs (Sucrose VLPs, purified according to
procedure B in Fig. 1a), heat-denatured NoV VLPs (60C, 1 h) (Heat-
treated VLPs) and CsCl-purified VLPs (CsCl VLPs) were tested for
binding to H type 3 and Lewisb carbohydrates at the indicated
concentrations. The pH value in the binding assay was 7.4
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respectively) were homogenous and intact, and approxi-
mately 38 nm in size. However, CsCl-purified VLPs
appeared heterogeneous in size, with a few broken parti-
cles, although comparable to the morphology seen by
others [7]. CsCl purification is known to introduce several
impurities at the end of the process and cause aggregation
of the VLPs during storage [5]. The poorest morphology
was seen after concentration of the VLPs by dialysis
against PEG, which resulted in aggregation. In addition,
residual PEG, which leaks through the dialysis membrane,
might interfere with further applications of the VLPs [19].
Our data clearly demonstrate that the purification process
affects the integrity of the native quaternary structure of NoV
VLPs and, subsequently, the receptor-binding functionality
of the VLPs. Although the majority of the VLPs purified by
the CsCl method seemed intact in the EM image, the differ-
ence from sucrose-density-gradient-purified VLPs in HBGA
binding is striking. This result is supported by the recent
finding that CsCl has a negative impact on the functionality of
VLPs [5]. We also demonstrated that even heat-disrupted
VLPs have binding capability, but intact homogenous VLPs
have a significantly greater binding intensity. Standardiza-
tion of the purification method for NoV VLPs used in diag-
nostic serological assays and blocking assays [8] would
greatly strengthen the results obtained.
To the best of our knowledge, this is the first time that
VLPs purified by conventional purification and concen-
tration methods were compared in terms of yield, purity,
morphological integrity, antigenicity and functionality. The
results show that NoV GII-4 VLPs purified twice by
sucrose density gradient centrifugation followed by ultra-
filtration maintain their icosahedral capsid structure and
their capacity to bind HBGAs.
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